Modelling the potential clinical and economic impact of universal immunisation with nirsevimab versus standard of practice for protecting all neonates and infants in their first respiratory syncytial virus season in Spain
These results suggest that immunisation with nirsevimab of all infants experiencing their first RSV season in Spain is likely to prevent thousands of RSV-related health events and save considerable costs versus the current SoP.
Authors
- Javier Álvarez Aldeán
- Juan Luis López-Belmonte (ORCID: https://orcid.org/0000-0001-8849-6415)
- Paulina Kaźmierska
- Julie Roïz (ORCID: https://orcid.org/0000-0002-5597-5054)
- Aditya Sardesai (ORCID: https://orcid.org/0000-0002-4250-4747)
- Alexia Kieffer (ORCID: https://orcid.org/0009-0004-5735-195X)
- Georgina Drago (ORCID: https://orcid.org/0000-0002-1905-1313)
- Matthieu Beuvelet (ORCID: https://orcid.org/0000-0001-5450-3613)
- Ruth Gil-Prieto (ORCID: https://orcid.org/0000-0002-5229-3832)
- Solène de Boisvilliers
- Jaime Jesus Pérez
Institutions
- Ithaka Harbors (US)
- Universidad Rey Juan Carlos (ES)
- Sanofi (France) (FR)
- Directorate of Health (IS)
- Hospital Costa del Sol (ES)
- Sanofi (Spain) (ES)
- EVRAZ (United Kingdom) (GB)
Publication Details
- Journal
- BMC Infectious Diseases
- Published
- 2024-09-06
- DOI
- https://doi.org/10.1186/s12879-024-09642-0
- Citations
- 8
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 3.09
Funders
- AstraZeneca
- Sanofi
- University of Pittsburgh